Evidence map›Paper›PMID 42872207›Full record

ArticleCell biomaterials2026

Reverse the progression of Alzheimer's disease through Nano-ERASER-based adult neuroregeneration.

Mingming Wang, Brandon VanderVeen, Zhixuan Annie Xu, Ying Xu, Jacobo Mintzer, Angela Murphy, Quanguang Zhang, Peisheng Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mingming WangDepartment of Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA.
Brandon VanderVeenDepartment of Pathology, Microbiology & Immunology, School of Medicine, University of South Carolina, Columbia, SC, USA.
Zhixuan Annie XuDutch Fork High School, Irmo, SC, USA.
Ying XuDepartment of Anesthesiology, Rutgers University, the State University of New Jersey, Newark, NJ, United States.
Jacobo MintzerCollege of Health Professions, Medical University of South Carolina, Charleston, SC, USA.
Angela MurphyDepartment of Pathology, Microbiology & Immunology, School of Medicine, University of South Carolina, Columbia, SC, USA.
Quanguang ZhangDepartment of Neurology, Institute for Cerebrovascular and Neuroregeneration Research, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
Peisheng XuDepartment of Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA.

Funding

Microscopy and Flow Cytometry CoreP30GM154632 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI Chang-UK Lim · 2024 to 2026
$4.5M
Brain targeted nanoparticle for Alzheimer's disease therapyR01AG054839 · NIA · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI XU, PEISHENG · 2017 to 2021
$1.8M
Cancer cell selective killing nanoparticle for advanced ovarian cancer treatmentR01CA263747 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI Peisheng Xu · 2022 to 2026
$1.7M
Develop a novel strategy to deliver N-acetylcysteine for AD treatmentR41AG087769 · NIA · ACEPRE, LLC · PI FAN, DAPING, XU, PEISHENG · 2024 to 2024
$499k
NCI NIH HHS R01 CA263747NIA NIH HHS R01 AG054839NIA NIH HHS R41 AG087769NIGMS NIH HHS P30 GM154632
6 · The paper itself

Abstract

Alzheimer's disease (AD) remains irreversible largely because the adult brain cannot replace lost neurons. Here, we present a Nano-ERASER-based Trim-Away system (TN-PTBP1) that enables adult neuroregeneration in the AD brain, offering a new strategy to counteract AD progression. TN-PTBP1 penetrates the blood-brain barrier, delivers anti-PTBP1 antibodies into astrocytes, and triggers rapid TRIM21-mediated PTBP1 degradation. This non-genomic protein depletion induces astrocyte-to-neuron conversion, generates functional neurons

Identifiers

PMID42872207
PMCPMC13660790

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.